Suppr超能文献

可控递送系统在哮喘治疗中的潜力:基于黄酮类化合物治疗的临床前开发

Therapeutic Potential of Controlled Delivery Systems in Asthma: Preclinical Development of Flavonoid-Based Treatments.

作者信息

Borghi Sergio M, Zaninelli Tiago H, Carra Jéssica B, Heintz Olivia K, Baracat Marcela M, Georgetti Sandra R, Vicentini Fabiana T M C, Verri Waldiceu A, Casagrande Rubia

机构信息

Department of Pathology, Center of Biological Sciences, Londrina State University, Londrina 86057-970, PR, Brazil.

Center for Research in Health Sciences, University of Northern Paraná, Londrina 86041-120, PR, Brazil.

出版信息

Pharmaceutics. 2022 Dec 20;15(1):1. doi: 10.3390/pharmaceutics15010001.

Abstract

Asthma is a chronic disease with increasing prevalence and incidence, manifested by allergic inflammatory reactions, and is life-threatening for patients with severe disease. Repetitive challenges with the allergens and limitation of treatment efficacy greatly dampens successful management of asthma. The adverse events related to several drugs currently used, such as corticosteroids and β-agonists, and the low rigorous adherence to preconized protocols likely compromises a more assertive therapy. Flavonoids represent a class of natural compounds with extraordinary antioxidant and anti-inflammatory properties, with their potential benefits already demonstrated for several diseases, including asthma. Advanced technology has been used in the pharmaceutical field to improve the efficacy and safety of drugs. Notably, there is also an increasing interest for the application of these techniques using natural products as active molecules. Flavones, flavonols, flavanones, and chalcones are examples of flavonoid compounds that were tested in controlled delivery systems for asthma treatment, and which achieved better treatment results in comparison to their free forms. This review aims to provide a comprehensive understanding of the development of novel controlled delivery systems to enhance the therapeutic potential of flavonoids as active molecules for asthma treatment.

摘要

哮喘是一种患病率和发病率不断上升的慢性疾病,以过敏性炎症反应为特征,对重症患者有生命威胁。过敏原的反复刺激和治疗效果的局限性极大地阻碍了哮喘的成功管理。目前使用的几种药物(如皮质类固醇和β-激动剂)相关的不良事件,以及对既定方案的低严格依从性可能会影响更有效的治疗。黄酮类化合物是一类具有非凡抗氧化和抗炎特性的天然化合物,其潜在益处已在包括哮喘在内的多种疾病中得到证明。先进技术已用于制药领域以提高药物的疗效和安全性。值得注意的是,将这些技术应用于以天然产物作为活性分子也越来越受到关注。黄酮、黄酮醇、黄烷酮和查耳酮是在哮喘治疗的控释系统中进行测试的黄酮类化合物的例子,与它们的游离形式相比,这些化合物取得了更好的治疗效果。本综述旨在全面了解新型控释系统的发展,以增强黄酮类化合物作为哮喘治疗活性分子的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed6/9865502/4eaf84f7a111/pharmaceutics-15-00001-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验